Vipul Jairath
University of Western Ontario
311 Papers
250 Citations
Vipul Jairath is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 35, co-authored 88 publications. Previous affiliations of Vipul Jairath include NHS Blood and Transplant & University of Oxford.
Chat about Author
Papers
Reliability of histologic assessment in patients with eosinophilic oesophagitis.
Marijn J. Warners,C. A. Ambarus,Arjan Bredenoord,Joanne Verheij,Gregory Y. Lauwers,J. C. Walsh,David A. Katzka,Sigrid Nelson,T. van Viegen,Glenn T. Furuta,Sandeep Gupta,Larry Stitt,Guangyong Zou,Claire E Parker,Lisa M. Shackelton,G. R. D`Haens,W J Sandborn,Evan S. Dellon,Brian G. Feagan,Margaret H. Collins,Vipul Jairath,Rish K. Pai +21 more
TL;DR: The validity of the eosinophilic oesophagitis histologic scoring system (EoEHSS) has been demonstrated, but only preliminary reliability data exist.
51
Biosimilars in IBD: hope or expectation?
Krisztina B Gecse,Reena Khanna,Gijs R. van den Brink,Cyriel Y. Ponsioen,Mark Löwenberg,Vipul Jairath,Simon Travis,William J. Sandborn,Brian G. Feagan,Geert R. D'Haens +9 more
TL;DR: This subject has received increasing attention in gastroenterology, because the patent on infliximab is due to expire and regulatory approval for two biosimilar inflIXimabs have already been filed for to the European Medicines Agency (EMA).
51
Comparative Risk of Serious Infections with Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Virginia Solitano,Antonio Facciorusso,Tine Jess,Christopher Ma,Cesare Hassan,Alessandro Repici,Vipul Jairath,Alessandro Armuzzi,Siddharth Singh +8 more
TL;DR: In this paper , the authors performed a systematic review and meta-analysis comparing the risk of serious infections with advanced therapies in active comparator studies, including vedolizumab vs TNFα antagonists in all patients with inflammatory bowel diseases.
51
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
Christopher Ma,Jurij Hanžel,Remo Panaccione,William J. Sandborn,Geert R. D'Haens,Vineet Ahuja,Raja Atreya,Charles N. Bernstein,Peter Bossuyt,Brian Bressler,Robert V Bryant,Benjamin L Cohen,Jean-Frederic Colombel,Silvio Danese,Axel Dignass,Marla Dubinsky,Phillip Fleshner,Richard B. Gearry,Stephen B. Hanauer,Ailsa Hart,Paulo Gustavo Kotze,Torsten Kucharzik,Peter L. Lakatos,Rupert W. Leong,Fernando Magro,Julián Panés,Laurent Peyrin-Biroulet,Zhihua Ran,Miguel Regueiro,Siddharth Singh,Antonino Spinelli,A. Hillary Steinhart,Simon Travis,C. Janneke van der Woude,Bruce R. Yacyshyn,Takayuki Yamamoto,Matthieu Allez,Willem A. Bemelman,Amy L. Lightner,Edouard Louis,David T. Rubin,Ellen Scherl,Corey A. Siegel,Mark S. Silverberg,Severine Vermeire,Claire E Parker,S. Mcfarlane,Leonardo Guizzetti,Michelle I. Smith,Niels Vande Casteele,Brian G. Feagan,Vipul Jairath +51 more
TL;DR: This multidisciplinary collaboration involving patients and clinical experts has produced the first COS that can be applied to RCTs of Crohn's disease and UC.
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease
Reena Khanna,Guangyong Zou,Larry Stitt,Brian G. Feagan,William J. Sandborn,William J. Sandborn,Paul Rutgeerts,John W.D. McDonald,Elena Dubcenco,Ronald Fogel,Remo Panaccione,Vipul Jairath,Sigrid Nelson,Lisa M. Shackelton,Bidan Huang,Qian Zhou,Anne M. Robinson,Barrett G. Levesque,Barrett G. Levesque,Geert D'Haens +19 more
TL;DR: Although both the SES-CD and CDEIS are valid measures of endoscopic disease activity that are moderately responsive to changes in endoscope disease activity, the S ES-CD displayed numerically greater responsiveness in this data set.
49